Little-known medical equipment and biotech companies jumped on Wall Street on Monday, following news that a nurse had become the first person to contract the deadly Ebola virus in the United States. Shares of biotechnology company Ibio Inc , hazmat suits maker Lakeland Industries Inc , and face mask maker Alpha Pro Tech Ltd were all higher near midday. Investors have piled into various companies … Continue reading Biotech Stock in News: A Look at Biotech Stocks Related to Ebola

While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in mind we three biotech stocks which have a good chance to turn things around; and here’s a quick look at each of them. Looking at their … Continue reading Biotech Stocks in News: Speculating the Best Biotech Stocks in the Market Currently

Last week, companies like Sunesis Pharmaceuticals, Inc (SNSS) and Chimerix, Inc (CMRX) were in the news due to pipeline updates. While Sunesis’ shares slumped on disappointing data, Chimerix made news related to the Ebola virus. Meanwhile, Regeneron’s (REGN) Eylea continues to gain approval for new indications. Sunesis’ shares tanked 78% on news that a pivotal phase III study being conducted on Qinprezo (vosaroxin) and cytarabine … Continue reading Biotech Stock News: A Look At All the Biotech Stocks For the Past Week

Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma companies to enter into agreements with larger pharma companies for … Continue reading Biotech Stock Incyte Receives $60M Milestone Payment

Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal vein occlusion (CRVO). We remind investors that Eylea is already … Continue reading Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA

Shares of Sunesis Pharmaceuticals, Inc (SNSS) plunged significantly after the company announced that its phase III trial, VALOR, failed to meet its primary endpoint. The randomized, double-blind, placebo-controlled trial (n=711) evaluated the efficacy of Qinprezo (vosaroxin) and cytarabine in patients suffering from first relapsed or refractory acute myeloid leukemia (AML). The trial failed to reach its primary endpoint of a statistically significant improvement in overall … Continue reading Sunesis Pharmaceuticals Stock Down : Biotech Trial Failure